Tailor-made approach to photodynamic therapy in the treatment of cancer based on Bcl-2 photodamage

  • Authors:
    • Jitsuo Usuda
    • Takeshi Hirata
    • Shuji Ichinose
    • Taichirou Ishizumi
    • Tatsuya Inoue
    • Keishi Ohtani
    • Sachio Maehara
    • Masae Yamada
    • Hidemitsu Tsutsui
    • Tetsuya Okunaka
    • Harubumi Kato
    • Norihiko Ikeda
  • View Affiliations

  • Published online on: Wednesday, October 1, 2008
  • Pages: 689-696
  • DOI: 10.3892/ijo_00000054

Abstract

It is very important to elucidate the mechanism of action and identify the molecular determinant of photodynamic medicine, in order to increase the number of clinical applications of photodynamic therapy (PDT) and perform personalized medicine. We have previously reported that PDT using some photosensitizers, such as phthalocyanine 4 (Pc 4) damages the anti-apoptotic protein Bcl-2, and that Bcl-2 is a molecular PDT target using a mitochondrion-targeting photosensitizer. In this study, we examined the molecular targets of Photofrin-PDT and NPe6-PDT, which are approved for early stage lung cancers by the Japanese Ministry of Health Labor and Welfare, by evaluating the photodamage to Bcl-2 using Western blot analysis. Our results showed that Photofrin-PDT damaged Bcl-2, induced morphologically typical apoptosis, and demonstrated equal sensitivity between MCF-7c3 cells (human breast cancer cells expressing stably transfected procaspase-3) and Bcl-2 overexpressing cells, MCF-7c3-GFP-Bcl-2 cells, with a clonogenic assay. However, NPe6-PDT did not damage Bcl-2 and took longer to induce typical apoptosis compared with Photofrin-PDT. MCF-7c3-GFP-Bcl-2 cells were considerably more resistant to the lethal effects of NPe6-PDT than parental MCF-7c3 cells. In conclusion, Photofrin-PDT damages different molecular targets, and our data indicate that the extent of Bcl-2 photodamage can determine the sensitivity of cancer cells to apoptosis and to overall cell killing caused by PDT using Photofrin, but not the lysosomal targeting NPe6. The application of these findings to clinical PDT may depend on the levels of the Bcl-2 proteins in the tumor being treated, and the tailor-made medicine based on the Bcl-2 photodamage may overcome any resistance afforded by elevated amounts of Bcl-2.
Journal Cover

October 2008
Volume 33 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

2013 Impact Factor: 2.773
Ranked #30/202 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Usuda, J., Hirata, T., Ichinose, S., Ishizumi, T., Inoue, T., Ohtani, K., Maehara, S., Yamada, M., Tsutsui, H., Okunaka, T., Kato, H., & Ikeda, N. (2008). Tailor-made approach to photodynamic therapy in the treatment of cancer based on Bcl-2 photodamage. International Journal of Oncology, 33(4), 689-696.
MLA
Usuda, Hirata, Ichinose, Ishizumi, Inoue, Ohtani, Maehara, Yamada, Tsutsui, Okunaka, Kato, and Norihiko Ikeda. "Tailor-made approach to photodynamic therapy in the treatment of cancer based on Bcl-2 photodamage." International Journal of Oncology International Journal of Oncology 33.4 (2008): 689-696.
Chicago
Usuda, Hirata, Ichinose, Ishizumi, Inoue, Ohtani, Maehara, Yamada, Tsutsui, Okunaka, Kato, and Norihiko Ikeda. "Tailor-made approach to photodynamic therapy in the treatment of cancer based on Bcl-2 photodamage." International Journal of Oncology International Journal of Oncology 33 no. 4 (2008): 689-696.